retatrutide 2 week results 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and type diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Effects of once-weekly subcutaneous retatrutide

In rough trial comparisons, Retatrutides TRIUMPH-1 data shows around 28.3% mean weight loss at 80 weeks on the 12 mg dose, with up to 30.3% at 104 weeks in a select extension population

Storage Store refrigerated between uses as per research protocol

Current science does not support true Ozempic patches, and no FDA approved transdermal GLP-1 medication exists as of March 2026

Creutzfeldt W

Health Conditions A-Z Health & Wellness Nutrition Fitness Health News Ayurveda Videos Medicine A-Z Parenting Login to get the latest articles, videos, gallery, and a lot more or continue with Email Google Facebook To get Registered Signup now Credit: AI Updated Jul 27, 2026 | 09:00 PM IST Summary As the number of Ozempic, Wegovy, and Mounjaro users has increased significantly, the viral trend of GLP-1 microdosing has raised concerns